Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR

Stephan Borte,1,2,3,4 Ulrika von Döbeln,5 Anders Fasth,6 Ning Wang,1 Magdalena Janzi,1 Jacek Winiarski,7 Ulrich Sack,2,3 Qiang Pan-Hammarström,1 Michael Borte,4 and Lennart Hammarström1

1 Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden; 2 Institute of Clinical Immunology, Medical Faculty, University of Leipzig; 3 Translational Centre for Regenerative Medicine (TRM), University of Leipzig, Germany; 4 ImmunoDeficiencyCenter Leipzig (IDCL) at Hospital St. Georg gGmbH Leipzig, Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies Leipzig, Germany; 5 Division of Metabolic Diseases, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden; 6 Department of Pediatrics, The Sahlgrenska Academy, University of Gothenburg, Sweden; 7 Division of Pediatrics (CLINTEC), Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden.

Address correspondence to Stephan Borte or Lennart Hammarström, Division of Clinical Immunology F79, Karolinska Institutet at Karolinska University Hospital Huddinge, SE141-86 Stockholm, Sweden. Phone: (+49) 175 987 15 31, Fax: (+49) 341 6522 9512, eMail: Stephan.Borte@ki.se, Lennart.Hammarstrom@ki.se

Key words: T-cell receptor excision circles, TREC, kappa-deleting recombination excision circles, KREC, primary immunodeficiency diseases, SCID, XLA, Ataxia telangiectasia, neonatal screening

Designated scientific section: IMMUNOBIOLOGY
Abstract

Severe combined immunodeficiency (SCID) and X-linked agammaglobulinemia (XLA) are inborn errors of immune function that require prompt diagnosis and treatment to prevent life-threatening infections. The lack of functional T- or B-lymphocytes in these diseases serves as a diagnostic criterion and can be applied to neonatal screening. A robust triplex PCR method for quantitation of T cell receptor- (TREC) and kappa-deleting recombination excision circles (KREC), using a single Guthrie card punch, was developed and validated in a cohort of 2,560 anonymized newborn screening cards and in 50 original stored Guthrie cards from patients diagnosed with SCID, XLA, Ataxia-telangiectasia (AT), Nijmegen-breakage-syndrome (NBS), Common variable immunodeficiency (CVID), Immunoglobulin-A-deficiency (IgAD), or X-linked Hyper-IgM-syndrome (X-HIGM). Simultaneous measurement of TREC and KREC copy numbers in Guthrie card samples readily identified patients with SCID, XLA, AT and NBS and thus facilitates effective newborn screening for severe immunodeficiency syndromes characterized by the absence of T or B cells.
Introduction

Primary immunodeficiencies (PID) comprise a group of more than 200 different diseases.\textsuperscript{1} The clinical severity ranges from mild to potentially life-threatening. Major efforts are currently being undertaken to develop methods for detection of PID in the neonatal period. PCR based detection of signal joint T cell receptor excision circles (TRECs), extracted from Guthrie cards, has previously proven to be a valuable tool for identifying patients with severe combined immunodeficiencies (SCID).\textsuperscript{2,3,4} Recently, a similar method for analysis of kappa-deleting excision circles (KRECs) was described, allowing identification of patients with X-linked agammaglobulinemia (XLA).\textsuperscript{5} The early identification of XLA patients is highly desirable, as the incidence of chronic lung disease in these patients results from delayed diagnosis and is one of the most detrimental factors on the prognosis and quality of life.\textsuperscript{6} To enable simultaneous screening of T- and B-cell deficiencies, we combined these assays into a novel triplex PCR method and evaluated its potential clinical application.

Patients and methods

Neonatal Guthrie card samples

Single 3.2-mm dried blood spot punches from 2,560 freshly collected, anonymized Guthrie cards (903\textsuperscript{®}, GE Healthcare, Chalfont St Giles, UK) and 29 stored original cards of patients diagnosed with SCID (n = 18), XLA (n = 4), Ataxia-telangiectasia (AT, n = 4) or Nijmegen-breakage-syndrome (NBS, n = 2) were included. Additionally, Guthrie card samples from patients with Common variable immunodeficiency (CVID, n = 4), Immunoglobulin A deficiency (IgAD, n = 15) or X-chromosome-linked Hyper-IgM-syndrome (X-HIGM, CD40L defect, n = 2) served as disease controls. All the included patients were retrospectively identified based on diagnoses made and none refused allocation of the stored original neonatal screening card. Dried blood spot samples were prepared within the first 72 hours after birth. The KREC level of one of the XLA patients has been described in our previous publication.\textsuperscript{5}
DNA elution from dried blood spot punches

Upon the approval of the institutional review board at the Karolinska University Hospital Huddinge, DNA from a single 3.2-mm punch of the dried blood disks was eluted into 24 µl of Generation DNA Elution Solution (Qiagen, Hilden, Germany) supplemented with 100 µg/ml yeast tRNA (Ambion, Austin, TX, USA), and 8 µl were subjected to real-time quantitative PCR (RT-qPCR) of TREC, KREC, and β-actin (ACTB). TREC and KREC copy numbers were normalized per µl blood, assuming that a 3.2-mm punch contains ~3 µl of whole blood. The triplex RT-qPCR assay was optimized by primer limitation and probe concentration with primers and probes specific for the signal joint of TREC and KREC or for ACTB to assure equal amplification efficacies. ACTB amplification was used to assess the success of DNA extraction from the Guthrie cards.

Real-time quantitative triplex PCR

The RT-qPCR reactions were performed in a final volume of 20 µl containing 1XTaqMan Gene Expression Master Mix, 20 µM TREC primers, 25 µM KREC primers, 7.5 µM ACTB primers, 15 µM of 6FAM-labeled MGB TREC and NED-labeled MGB ACTB probes, 17.5 µM VIC-labeled MGB KREC probe (all from Applied Biosystems, Austin, TX, USA) and 0.8 µl BSA 10 mg/ml (New England Biolabs, Ipswich, MA, USA). The 96-well plate reactions were carried out on ABI 7500 and ViiA7 real-time PCR systems (Applied Biosystems) with an initial cycle at 50°C for 2 min, a heating cycle at 95°C for 10 min, followed by 45 cycles of 30 seconds at 95°C and 30 seconds at 60°C. An individual cycle threshold for TREC, KREC or ACTB was fixed for automated data collection and analysis of the amplification during the exponential phase. Calibration curves were generated by 10-fold serial dilution using a TREC-KREC-TRAC (TCRα subunit constant gene) construct containing plasmid and a β-actin sequence containing plasmid, and all analyzed RT-qPCR assays fulfilled the quality requirements of similar slopes and R² values >0.97.
Sequence analysis of PID genes

Genomic DNA, eluted from the dried blood spot punches of previously identified SCID patients, was used to amplify the coding regions of the RAG1, RAG2, IL2RG, IL-7RA or AK2 genes in order to verify mutations. Subsequent to gel electrophoresis, PCR products were purified (MSB Spin PCRapace, Stratec, Berlin, Germany) and sent for direct sequencing (IZKF, University of Leipzig, Germany).

Results and Discussion

Cutoff values for reliable identification of SCID and XLA patients

Based on the KREC and TREC copy numbers of the included SCID and XLA patients and repeat testing of all 2,560 anonymized samples, suitable diagnostic cutoff scores were established at 15 TRECs/µl and 10 KRECs/µl. Given screening demands, cutoff scores were optimised to correctly identify the included samples from patients diagnosed with SCID or XLA with a sensitivity of 1.0 at expense of the specificity of the test (Fig. 1). Employing these cutoffs, the disease control samples from patients with CVID, IgAD and X-HIGM, as expected, all fell within the normal range. However, as the diagnosis of these antibody deficiency syndromes is often delayed in childhood, leading to development of lung damage and lymphoid proliferative disease, and given that effective treatment strategies exist in pediatric patients, efforts are indicated to allow an early-as-possible diagnosis of these diseases. Of interest, all 4 patients with AT showed a marked reduction of both TRECs and KRECs, and both patients with NBS were identified based on solely low KREC copy numbers (Fig. 1). The TREC and KREC levels upon re-testing of the AT and NBS patients, as well as available clinical and routine laboratory information is given in supplementary table 1. This implies that the method might also identify some patients with chromosome instability syndromes, who are commonly not recognised before the onset of symptoms in early...
childhood. Repeat testing of all included PID patients, using either the original DNA eluate or DNA from a second dried blood spot, provided consistent results (data not shown).

To assess the overall reproducibility of the assay, 160 duplicate control samples were analyzed on different PCR systems (ABI 7500 and ViiA7). Within the dynamic range of copy numbers with excellent linearity, the intra-assay coefficient of variation was 1.2% for TREC/µl and 1.4% for KREC/µl. The inter-assay variance coefficient of variation was 3.5% for TREC/µl and 4.2% for KREC/µl, indicating that our triplex RT-qPCR assay exhibits a robustness and reproducibility that meets diagnostic requirements.

**Concordance of SCID immunophenotypes with TREC and KREC copy numbers**

To conform with the diagnostic demands of neonatal screening, this study included only samples from the originally stored Guthrie cards of 18 SCID patients. All patients with confirmed mutations in the *RAG1* gene demonstrated out-of-range values for both TREC and KREC, paralleling the T⁻ B⁻ (NK⁺) immunophenotype, and none of the SCID patients with copy numbers of >10 KREC/µl was found to have *RAG1* mutations (Fig. 1). In patients with verified *IL2RG* mutations, KREC copy numbers were comparable to that of healthy newborns, reflecting the T⁻ B⁺ (NK⁺) immunophenotype of X-SCID patients. On the other hand, no mutations in the *IL2RG* gene were demonstrated in SCID patients with absent KREC (Fig. 1). Thus, our triplex PCR assay could be of value to guide the molecular diagnosis with regard to different types of SCID.

**Diagnostic procedures for routine prospective Guthrie card analysis**

Guthrie card samples with ACTB copy numbers below 1000/µl and concomitant reduction of TREC and KREC were referred to as ‘inconclusive’ due to a lack of DNA starting sample. Thus, a second punch was repeatedly tested (n = 6; 0.23% of total), resulting in normal findings for 5 of these samples which is in the range of previous reports. Guthrie card samples with TREC or KREC copy numbers below the respective cutoff values were
considered ‘abnormal’ and likewise subjected to repeat testing. Seven such samples (0.27% of total) were re-tested due to low TREC numbers (<15 TREC/µl), eight samples (0.31% of total) due to low KREC numbers (<10 KREC/µl), and one due to a combined reduction of both markers. The repeat testing of a second dried blood disk from the original cards yielded normal results for 10 samples (Fig. 2). As the Guthrie cards used in this study were anonymized, the underlying cause for the T- or B-lymphopenia in the remaining 6 samples (0.23% of total) is unknown, but might be due to patients with the DiGeorge’s syndrome (22q11 deletion syndrome), Trisomy 21, and others.\textsuperscript{11} Furthermore, the presence of congenital abnormalities and complications due to prematurity have been shown to increase the number of abnormal test results from excision circle assays, as will the detection of additional combined immunodeficiencies such as \textit{DOCK8} deficiency.\textsuperscript{12,13} This observation is likely to be expanded to isolated abnormal KREC copy numbers, as presented herein for the included samples from NBS patients. The clinical significance of low KREC levels therefore deserves further investigation and will be the subject of two large-scale prospective studies in Sweden and Germany.

To assure the diagnostic suitability of the retesting procedure, all Guthrie card samples with previously ‘normal’ results were repeatedly tested using the original DNA eluate (data not shown). None of these samples reversed into either the ‘abnormal’ or ‘inconclusive’ category, indicating that the result of the analysis is inherently determined by the starting DNA sample, and not by the triplex PCR method. In the light of the screening purpose of our method, and given that results in tested PID patients did not change upon re-analysis, the repeat testing of a second Guthrie card disk is a reliable and meaningful procedure that is also warranted in view of the low percentage of abnormal and inconclusive samples (0.86% of total).

The observation that patients with the chromosome instability disorders Ataxia telangiectasia or Nijmegen-breakage-syndrome could be detected, based on out-of-range levels for TREC or KREC in the original Guthrie cards, requires further considerations to conform with the
tracking process of neonatal screening programmes. Most importantly, these diseases should be taken into account upon clinical assessment of potential patients, as features such as microcephaly or bird-like faces can be initial hallmarks. While genotyping common founder mutations in NBS is a useful diagnostic approach, the detection of elevated alpha-fetoprotein serum levels or truncations of the ATM protein is more practicable in AT. The therapeutic perspective for AT and NBS patients has made considerable progress during recent years, providing evidence for successful stem cell transplantation in NBS and slowdown of neurodegeneration in AT using antioxidants and PARP inhibitors. Novel treatment strategies might also arise from the use of translational read-through compounds to correct the ATM gene function, while the substitution of immunoglobulin preparations is commonplace practice to treat the humoral immunodeficiency in NBS and to improve the clinical outcome.

In summary, a triplex RT-qPCR measuring the levels of TRECs and KRECs provides a suitable screening for the vast majority of severe immunodeficiency diseases characterised by T- or B-lymphopenia in newborns.

Acknowledgements

The authors are indebted to John M. Routes and Mei W. Baker for helpful discussions and excellent technical guidance and support. We also thank Alessandra Sottini and Luisa Imberti for supplying a TREC-KREC-TRAC plasmid, as well as William J. Grossmann and Donna K. Mahnke for providing a β-actin sequence containing plasmid. We are furthermore grateful to Kerstin Krist for excellent technical skills in genomic sequence analysis.

Authorship

Contribution: S.B. performed and analyzed the research, created the figures and wrote the paper. N.W. and M.J. performed experiments and analyzed results. U.v.D., A.F., J.W., and
M.B. provided Guthrie card samples and were in charge for the diagnosis and treatment of involved PID patients. U.S. and Q.P.-H. designed the research. L.H. designed the research and wrote the paper. Conflict-of-interest disclosure: none of the authors declare competing financial interests. This work was supported in part by the European Research Council (242551-ImmunoSwitch), the Swedish Research Council, the German National Academic Foundation (to S.B.), the German Federal Ministry of Education and Research (BMBF, PtJ-Bio, 0315883), the Saxon State Ministry of Social Affairs (SMS) and the Jeffrey Modell Foundation (to M.B. and L.H.).
References


Figures

Fig. 1

TREC and KREC copy numbers in dried blood spot samples (DBSS) from anonymized Guthrie cards, re-tested samples and in patients diagnosed with SCID, XLA, AT, NBS, X-HIGM, CVID or IgAD. Dot size correlates with the amount of ACTB per sample. Dashed lines represent cutoff values for TREC/µl and KREC/µl, respectively. Proven molecular defects in the shown SCID patients are depicted as follows: RAG1 = recombination activating gene 1, IL2RG = interleukin 2 receptor gamma chain (X-SCID), AK2 = adenylate kinase 2, IL7RA = interleukin 7 receptor subunit alpha, JAK3 = Janus kinase 3, uncl. = unclassified defect.
Fig. 2

Flow chart of the triplex RT-qPCR assay, including results of 2,560 freshly collected, anonymized regular Guthrie cards from Swedish newborns. Repeat testing was carried out using a second dried blood spot punch from the same Guthrie card.
Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR

Stephan Borte, Ulrika von Döbeln, Anders Fasth, Ning Wang, Magdalena Janzi, Jacek Winiarski, Ulrich Sack, Qiang Pan-Hammarström, Michael Borte and Lennart Hammarström

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.